Abstract

ARMAS DE HERNANDEZ, MJ et al. Efecto del Zileuton, un inhibidor de la 5-lipoxigenasa en pacientes con Asma Moderada. AVFT [online]. 2002, vol.21, n.1, pp.28-38. ISSN 0798-0264.

ABSTRACT With the aim of evaluating the anti-asthmatic action of zileuton, a 5-lipoxygenase inhibitor; a group of 25 asthmatic patients with a Forced Expiratory Volume in the first second (FEV-1) between 40% and 70% of their predicted values, were enrolled in a double blind, randomized, parallel study. Patients initially received identical placebo during 1 week, then active treatment zileuton 600mg (8 patients); zileuton 400mg (8 patients) or placebo (8 patients) during 9 weeks. Zileuton produced an acute bronchodilation with an increase of FEV-1 at 30 minutes and persisting during three hour. Acute maximum increment was observed one hour post dose; FEV-1 increased 0.37 L (14.12%), from 2.99 ± 0.22 L (p<0.001); Forced Vital Capacity (FVC) increased in 12.29% from 4.02 ± 0.46 L (p<0.005) and the Peak Expiratory Flow Rate (PEFR) increased in 13.7% (p < 0.005). After 9 weeks of treatment, zileuton produced and increased of the pulmonary function; as well as, reduction in asthmatic symptoms; the mayor increment observed occurred in zileuton 600mg group; where FEV-1 increased to 0.48 L from the base line (18.67%) p< 0.002; in comparison to 0.07 L in the placebo group. The diurnal and nocturnal symptoms decreased 92.30% (p<0.005) in the zileuton 600mg group, 41.05% in the zileuton 400mg group (p < 0.01) and 13.66% in the placebo group (NS). Transaminase levels increased in two patients; one in the zileuton 600mg group and one in the placebo group, both patients return to normal values at the end of the study. In conclusion, the treatment with a 5-lipoxygenase inhibitor produced a better control of asthma symptoms, both clinical and functional.

Keywords : Asthma; Pulmonary function; Zileuton; 5-lipoxygenase inhibitors.